Lucent Drugs Private Limited, a active private limited company, was established on 02 August 2017 in Sanathnagar, Telangana, India. Engaging in medicinal chemical & botanical products within the manufacturing sector, it holds CIN: U24100TG2017PTC118662. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹9.00 Cr and a paid-up capital of ₹6.28 Cr.
It upholds a compliant status. Employing 63 professional, Its leadership includes Sreenivasulu Devarasetty (Director), Mahaveer Chand Jain (Director). Past directors included Sai Vikas Devarasetty, Vinod Jain, Mahaveer Chand Jain. It holds ₹19.54 Cr open charges and ₹16.10 Cr settled loans. Its latest AGM occurred on 28 September 2024, with the balance sheet filed on 31 March 2024. It is based at Flat No.W-109,Svss Nivas, Oppo.Gokul Theatre Czech Colony,Street No.1, Sanathnagar, Telangana, 500018.
U24100TG2017PTC118662
118662
02 August 2017
₹9.00 Cr
₹6.28 Cr
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into Lucent Drugs Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sreenivasulu Devarasetty | Director | 02 Aug 2017 | Current |
| Mahaveer Chand Jain | Director | 14 Jun 2022 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 30 Sep 2022 | Past |
| Pramod Abcsdd | Director | 01 Apr 2019 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2022 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Lucent Drugs Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 8.35% decrease. The company also saw a substantial fall in profitability, with a 29.85% decrease in profit. The company's net worth Soared by an impressive increase of 52.01%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Lucent Drugs had a promoter holding of 73.63% and a public holding of 26.37%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹195,448,950.00
₹161,000,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Mar 2025 | Hdfc Bank Limited | ₹2.02 M | Open |
| 26 Aug 2024 | Standard Chartered Bank | ₹18.89 Cr | Open |
| 02 Dec 2022 | Hdfc Bank Limited | ₹2.33 M | Open |
| 21 Oct 2022 | Hdfc Bank Limited | ₹2.21 M | Open |
| 28 Mar 2018 | State Bank Of India | ₹16.10 Cr | Satisfied |
Explore comprehensive loan charge details -
Lucent Drugs has a workforce of 63 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Lucent Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lucent Drugs's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on A charge with Standard Chartered Bank of Rs. 18.89 Cr registered on 26 Aug 2024 with Charge ID 100986511 was modified on 27 Jun 2025. was documented.
The activity A charge registered on 28 Mar 2018 via Charge ID 100173302 with State Bank Of India was fully satisfied on 24 Mar 2025. was completed.
A charge with Hdfc Bank Limited amounted to Rs. 0.20 Cr with Charge ID 101071437 was registered on 21 Mar 2025. was recorded as a recent event.
The activity Lucent Drugs Private Limited last Annual general meeting of members was held on 28 Sep 2024 as per latest MCA records. was completed.
The activity A charge with Standard Chartered Bank amounted to Rs. 18.89 Cr with Charge ID 100986511 was registered on 26 Aug 2024. was completed.
Progress on Lucent Drugs Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Hyderabad. was documented.
The CIN of Lucent Drugs Private Limited is U24100TG2017PTC118662.
Lucent Drugs Private Limited is headquartered at Flat No.W-109,Svss Nivas, Oppo.Gokul Theatre Czech Colony,Street No.1, Sanathnagar, Telangana, 500018.
Lucent Drugs Private Limited was incorporated on 02 August 2017.
The current directors of Lucent Drugs Private Limited are
The primary industry of Lucent Drugs Private Limited is Manufacturing.
Lucent Drugs Private Limited is unlisted.
The authorized capital of Lucent Drugs Private Limited is ₹9.00 Cr, and the paid-up capital is ₹6.28 Cr.
The compliance status of Lucent Drugs Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX